Total Marrow Irradiation Added to an Alkylator-Intense Conditioning Regimen for Patients With High Risk or Relapsed Solid Tumors
This study has been terminated.
(Replaced by another study)
Sponsor:
Masonic Cancer Center, University of Minnesota
Information provided by (Responsible Party):
Masonic Cancer Center, University of Minnesota
ClinicalTrials.gov Identifier:
NCT00623077
First received: February 22, 2008
Last updated: June 11, 2013
Last verified: June 2013
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
RATIONALE: A peripheral blood stem cell transplant or bone marrow transplant using stem cells from the patient may be able to replace immune cells that were destroyed by chemotherapy and image-guided intensity-modulated radiation therapy used to kill tumor cells.
PURPOSE: This phase I trial is studying the side effects and best dose of bone marrow radiation therapy followed by an autologous stem cell transplant in treating patients with high-risk or relapsed solid tumors.
| Condition | Intervention | Phase |
|---|---|---|
|
Brain and Central Nervous System Tumors Kidney Cancer Liver Cancer Retinoblastoma Sarcoma |
Biological: filgrastim Drug: busulfan Drug: etoposide Drug: ifosfamide Drug: melphalan Drug: thiotepa Procedure: stem cell transplantation Radiation: tomotherapy Radiation: total marrow irradiation Drug: Mesna Radiation: Whole lung radiation |
Phase 1 |
| Study Type: | Interventional |
| Study Design: | Endpoint Classification: Safety/Efficacy Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Dose Escalation of Total Marrow Irradiation Added to an Alkylator-Intense Conditioning Regimen for Patients With High Risk or Relapsed Solid Tumors |
Resource links provided by NLM:
Drug Information available for:
Thiotepa
Busulfan
Melphalan
Melphalan hydrochloride
Ifosfamide
Mesna
Etoposide
Etoposide phosphate
Filgrastim
Sargramostim
Lenograstim
Granulocyte colony-stimulating factor
U.S. FDA Resources
Further study details as provided by Masonic Cancer Center, University of Minnesota:
Primary Outcome Measures:
- Maximum tolerated dose of tomotherapy up to 12 Gy [ Time Frame: Day 42 ] [ Designated as safety issue: Yes ]is a state-of-the- art means of delivering highly conformal radiation to tumors of targeted volume with high therapeutic gain. Tomotherapy offers unique advantages over total body irridiation and is expected to improve clinical outcome. The MTD is defined as the highest dose studied for which the incidence of dose limiting toxicity is less than 33%.
Secondary Outcome Measures:
- Percent of patients who had PET scans and "spot radiation" to PET-positive lesions after transplantation [ Time Frame: Day 60 Post Transplant ] [ Designated as safety issue: No ]PET-CT scan is done prior to and after transplant. Radiation is given before and after transplant.
- Change in bone mineral density [ Time Frame: Baseline, 6 and 12 Months Post Transplantation ] [ Designated as safety issue: Yes ]the change in bone density and turnover in patients exposed to alkylator intensive conditioning regimen followed by tomographic total marrow irradiation (TMI).
- Rate of Treatment Related Mortality in Non-TMI Treated Patients [ Time Frame: Day 100 Post Transplant ] [ Designated as safety issue: Yes ]Determined in patients who were not treated with total marrow irradiation; all deaths without previous relapse or progression are usually considered as related to transplantation.
- Rate of Primary Neutrophil Engraftment [ Time Frame: Day 42 ] [ Designated as safety issue: No ]Neutrophil engraftment is defined as the first day of three consecutive days where the neutrophil count (absolute neutrophil count) is 500 cells/mm3 (0.5 x 109/L) or greater.
- Overall Survival [ Time Frame: From date of enrollment to date of death or censored at the date of last documented contact ] [ Designated as safety issue: No ]Determined in patients not receiving total marrow irradiation. The percentage of people in a study or treatment group who are alive for a certain period of time after they were diagnosed with or treated for a disease, such as cancer. Also called survival rate.
- Disease-Free Survival [ Time Frame: 1 Year ] [ Designated as safety issue: No ]In patients not receiving total marrow irradiation, the length of time after treatment ends that a patient survives without any signs or symptoms of that cancer or any other type of cancer. In a clinical trial, measuring the disease-free survival is one way to see how well a new treatment works.
| Enrollment: | 23 |
| Study Start Date: | August 2005 |
| Estimated Study Completion Date: | June 2014 |
| Primary Completion Date: | July 2012 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: Total Marrow Irradiation (MTI) with Tomotherapy
TMI given prior to alkylator intensive conditioning regimen (Busulfan 9.6 mg/kg intravenously (IV) (>4 yrs of age) or 13.2 mg/kg IV (< 4 years of age), Melphalan 100 mg/m^2, Thiotepa 500 mg/m^2 for high risk solid tumor patients, Whole lung radiation 1500cGy in 10 fractions by Day 60, stem cell transplantation on day 0. Ifosfamide, etoposide, and mesna are given Days 0-4 followed by filgrastim for 3 doses. Cohorts of patients (n=3) will be treated with increasing doses of TMI (600, 1000, 1200 cGy) directed toward the bones.
|
Biological: filgrastim
Beginning 24 hours after chemotherapy end: 10 microgram/kg/day subcutaneously (SQ) or intravenously (IV) until absolute neutrophile count (ANC) > 1,000/mm^2. Starting that day, increase dose to 15 microgram/kg/day SQ or IV given as a single injection for 3 doses. Other Names:
Drug: busulfan
Part of pre-transplant conditioning chemotherapy: Administered as Busulfan 9.6 mg/kg IV (>4 yrs of age) or 13.2 mg/kg IV (< 4 years of age),every 6 hours on Days -8 through -6.
Other Names:
Drug: etoposide
Part of Mobilization chemotherapy and Peripheral blood progenitor cell collections (day -100 to -30): Given as 100 mg/m^2/day intravenous (IV) over 1 hour for 5 days.
Other Names:
Drug: ifosfamide
Part of Mobilization chemotherapy and Peripheral blood progenitor cell collections (day -100 to -30): Given as 1.8 g/m^2/day intravenous (IV) over 1 hour on for 5 days.
Other Names:
Drug: melphalan
Part of pre-transplant conditioning chemotherapy: Administered as 100 mg/m^2 intravenous (IV) over 30 min on Days -5 through -4.
Other Name: Alkeran
Drug: thiotepa
Part of pre-transplant conditioning chemotherapy: Administered as 500 mg/m^2 intravenously (IV) over 2 hrs on Days -3 through -2.
Other Name: ThioTEPA
Procedure: stem cell transplantation
Regardless of whether the patient will be receiving peripheral cells or bone marrow, infusion will be intravenous on day 0, immediately after thawing.
Other Name: HPC infusion
Radiation: tomotherapy
We plan to deliver the total marrow irradiation (TMI) to the upper half of the body using Tomotherapy TMI as explained in this protocol. However the lower part of the body will be treated with Anterior/Posterior linac based radiation treatment. Tomotherapy will then be delivered at a dose rate so as to keep the total treatment time to no more than 30 minutes. We anticipate that the dose rate will be around 400 cGy /minute (instantaneous dose rate). TMI will be delivered to all bony sites as part of the conditioning. Additional "spot" therapy to PET positive lesions, primary disease (if not previously irradiated to maximum tolerated dose), and lungs will be performed on Day +60. Cohorts of 3 patients will be treated at a total dose of 600 cGy, 900 cGy or 1200 cGy on Days -11 through -9.
Drug: Mesna
Part of Mobilization chemotherapy and Peripheral blood progenitor cell collections (day -100 to -30): Given as 1.8 g/m^2/day divided in every 6 hrs dosing for 5 days.
Other Names:
Radiation: Whole lung radiation
At Day 60, patients with prior lung metastasis should receive whole lung irradiation (1500cGy in 10 fractions).
|
Show Detailed Description Eligibility| Ages Eligible for Study: | up to 70 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
Diagnosis Patients must have had histologic verification of malignancy at original diagnosis. Diseases included are:
- Ewing's Family Tumors (ES/PNET/DSRCT): metastatic at the time of diagnosis and/or relapsed after therapy
- Renal tumors: relapsed (all histology-Wilm's tumor) or at diagnosis (clear cell sarcoma and Rhabdoid tumor),
- Hepatoblastoma: metastatic at the time of diagnosis and/or relapsed after therapy
- Rhabdomyosarcoma: metastatic at the time of diagnosis and/or relapsed after therapy
- Soft tissue sarcomas: chemotherapy responsive metastatic disease or chemotherapy responsive relapsed disease
- Primary Malignant Brain Neoplasms at diagnosis and/or relapse
- Retinoblastoma: disseminated at diagnosis and/or relapsed
- Other High Risk Metastatic or Relapsed Solid Tumors: To be approved by two or more physicians on the study committee
- Disease Status: Patients must have either: 1) no evidence of disease or 2) stable, non-progressive disease (defined as non-progressive abnormalities on physical exam or computated tomography (CT) and/or magnetic resonance imaging [MRI]) within 4 weeks of study entry.
- Age: Patients must be 0-70 years of age at the time of study entry.
- Performance Level: Karnofsky > or = 50% for patients > 10 years of age and Lansky > or = 50% for patients < or = 10 years of age. Note: Neurologic deficits in patients with central nervous system (CNS) tumors must be stable for a minimum of 1 week prior to study entry.
Organ Function:
- Hematologic: prior to receiving total marrow irradiation (TMI) patients should have a hemoglobin of >10 gm/dl and a platelet count > 20,000/μl. Patients may receive transfusions as necessary.
- Renal: glomerular flow rate (GFR) ≥ 50 ml/min/1.73m^2 or serum creatinine ≤ 2.5 x upper limit of normal (ULN) for age
- Hepatic: aspartate aminotransferase/alanine aminotransferase (AST or ALT) ≤ 5 x ULN and bilirubin ≤ 5 x ULN
- Cardiac: ejection fraction > 45% or no clinical evidence of heart failure
- Pulmonary: oxygen saturation > 92% at rest (on room air)
Exclusion Criteria:
- Disease Status: patients with progressive, non-therapy responsive disease will not be eligible.
- Infection: patients who have active, uncontrolled infections or those who are HIV+.
- Pregnancy or Breast-Feeding: pregnant or breast-feeding women will not be entered on this study.
- Prior Radiation Therapy: patients must be eligible to receive TMI via tomographic radiation therapy (as determined by radiation oncology staff). If not eligible (due to extensive prior radiation or other circumstances), patients can be treated on study but will not receive radiation and will be analyzed on a separate arm.
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00623077
Locations
| United States, Minnesota | |
| Masonic Cancer Center at University of Minnesota | |
| Minneapolis, Minnesota, United States, 55455 | |
Sponsors and Collaborators
Masonic Cancer Center, University of Minnesota
Investigators
| Principal Investigator: | Michael R. Verneris, MD | Masonic Cancer Center, University of Minnesota |
More Information
Additional Information:
No publications provided
| Responsible Party: | Masonic Cancer Center, University of Minnesota |
| ClinicalTrials.gov Identifier: | NCT00623077 History of Changes |
| Other Study ID Numbers: | 2005LS023, UMN-MT2004-30, 0504M69306 |
| Study First Received: | February 22, 2008 |
| Last Updated: | June 11, 2013 |
| Health Authority: | United States: Food and Drug Administration |
Keywords provided by Masonic Cancer Center, University of Minnesota:
|
metastatic Ewing sarcoma/peripheral primitive neuroectodermal tumor recurrent Ewing sarcoma/peripheral primitive neuroectodermal tumor childhood hepatoblastoma recurrent childhood liver cancer stage IV childhood liver cancer adult primary liver cancer previously treated childhood rhabdomyosarcoma recurrent childhood rhabdomyosarcoma previously untreated childhood rhabdomyosarcoma metastatic childhood soft tissue sarcoma recurrent childhood soft tissue sarcoma recurrent adult soft tissue sarcoma stage IV adult soft tissue sarcoma recurrent Wilms tumor and other childhood kidney tumors stage IV Wilms tumor |
stage V Wilms tumor rhabdoid tumor of the kidney stage IV renal cell cancer childhood mixed glioma recurrent childhood cerebellar astrocytoma recurrent childhood cerebral astrocytoma recurrent childhood ependymoma recurrent childhood medulloblastoma recurrent childhood pineoblastoma recurrent childhood supratentorial primitive neuroectodermal tumor recurrent childhood visual pathway glioma untreated childhood brain stem glioma untreated childhood cerebellar astrocytoma childhood infratentorial ependymoma childhood supratentorial ependymoma |
Additional relevant MeSH terms:
|
Carcinoma, Renal Cell Kidney Neoplasms Liver Neoplasms Nervous System Neoplasms Retinoblastoma Central Nervous System Neoplasms Neuroectodermal Tumors, Primitive Neuroectodermal Tumors, Primitive, Peripheral Sarcoma Adenocarcinoma Carcinoma Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Neoplasms Urologic Neoplasms |
Urogenital Neoplasms Neoplasms by Site Kidney Diseases Urologic Diseases Digestive System Neoplasms Digestive System Diseases Liver Diseases Nervous System Diseases Neoplasms, Neuroepithelial Neuroectodermal Tumors Neoplasms, Germ Cell and Embryonal Neoplasms, Nerve Tissue Retinal Neoplasms Eye Neoplasms Eye Diseases |
ClinicalTrials.gov processed this record on June 18, 2013